Stifel lowered the firm’s price target on Agilon Health (AGL) to $2 from $7 and keeps a Hold rating on the shares. Agilon has traded down 23% since the Q3 report and the firm expects it to remain depressed until it proves it can expand medical margin and accurately project medical expenses after the company’s profitability guidance was lowered significantly.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health price target lowered to $2 from $6 at TD Cowen
- Agilon Health price target lowered to $2 from $5 at Barclays
- Agilon Health downgraded to Market Perform from Outperform at JMP Securities
- Agilon Health price target lowered to $2 from $4 at Deutsche Bank
- Agilon Health downgraded to Market Perform from Outperform at William Blair